In situ gelling nasal inserts for influenza vaccine delivery

Drug Development and Industrial Pharmacy

Volumn 36, Issue 5, 2010, Pages 581-593

  Bertram, Ulrike ^a   Bernard, Marie Clotilde ^b   Haensler, Jean ^b   Maincent, Philippe ^c   Bodmeier, Roland ^a  

^a FREIE UNIVERSITÄT BERLIN   (Germany)

^b SANOFI PASTEUR   (France)

^c UNIVERSITÉ DE LORRAINE   (France)

Author keywords

Bioadhesive drug delivery systems; Enhancers; Extended release; Influenza vaccine; Nasal inserts; Nasal vaccination

Indexed keywords

CARBOMER; CARRAGEENAN; CATIONIC LIPID; CHITOSAN; HYDROXYPROPYLMETHYLCELLULOSE; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; IMMUNOLOGICAL ADJUVANT; INFLUENZA VACCINE; POLOXAMER; POLYARGININE; POVIDONE; SODIUM CHLORIDE; UNCLASSIFIED DRUG; XANTHAN;

ANIMAL EXPERIMENT; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DRUG DELIVERY SYSTEM; DRUG FORMULATION; DRUG RELEASE; DRUG STABILITY; ERYTHROCYTE; EXCIPIENT COMPATIBILITY; FEMALE; FREEZE DRYING; GELATION; HEMAGGLUTINATION; HYDROPHILICITY; IMMUNOGLOBULIN BLOOD LEVEL; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA VACCINATION; MOLECULAR WEIGHT; MOUSE; NASAL INSERT; NONHUMAN; PROTEIN BINDING; PROTEIN INTERACTION; VISCOSITY;

ADMINISTRATION, INTRANASAL; ANIMALS; DRUG CARRIERS; DRUG DELIVERY SYSTEMS; FEMALE; GELS; HEMAGGLUTININS, VIRAL; INFLUENZA A VIRUS, H1N1 SUBTYPE; INFLUENZA VACCINES; MICE; POLYSACCHARIDES, BACTERIAL; RATS; RATS, SPRAGUE-DAWLEY;

EID: 77952607745     PISSN: 03639045     EISSN: 15205762     Source Type: Journal    
DOI: 10.3109/03639040903382673     Document Type: Article

References (41)

1. Mestecky J, Moldoveanu Z, Michalek SM, Morrow CD, Compans RW, Schafer DP, et al. (1997). Current options for vaccine delivery by mucosal routes. J Control Release, 48: 243-57.
2. Merkus F W HM, Verhoef JC. (1994). Nasal drug delivery: Trends and Perspectives. In: Swarbrick J, Boyian JC, eds. Encyclopedia of pharmaceutical technology, vol. 10. New York: Marcel Dekker Inc., 191-220.
3. Kuper FC, Koornstra PJ, Hameleers D M H, Biewenga J, Spit BJ, Duijvestijn AM, et al. (1992). The role of the nasopharyngeal lymphoid tissue. Immunol Today, 13 (6): 219-24.
4. Jones N. (2001). The nose and the paranasal sinuses physiology and anatomy. Adv Drug Deliv Rev, 51: 5-19.
5. Gallichan WS, Rosenthal KL. (1995). Specific secretory immune response in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. Vaccine, 13: 1589-95.
6. Rudin A, Riise GC, Holmgren J. (1999). Antibody responses in the lower respiratory tract and male urogenital tract in humans after nasal and oral vaccination with cholera toxin B subunit. Infect Immun, 67: 2884-90.
7. Isaka M, Yasuda Y, Mizokami M, Kozuka S, Taniguchi T, Matano K, et al. (2001). Mucosal immunization against hepatits B virus by intranasal coadministration of recombinant hepatitis B surface antigen and recombinant cholera toxain B subunit as adjuvant. Vaccine, 19: 1460-6.
8. Lofthouse S. (2002). Immunological aspects of controlled antigen delivery. Adv Drug Deliv Rev, 54: 863-70.
9. Kemp JM, Kajihara M, Nagahara S, Sano A, Brandon M, Lofthouse S. (2002). Continuous antigen delivery from controlled release implants induces significant and anamnestic immune response. Vaccine, 20: 1089-98.
10. Glueck R. (2001). Review of intranasal influenza vaccine. Adv Drug Deliv Rev, 51: 203-11.
11. Barchfeld GL, Hessler AL, Chen M, Pizza M, Rappuoli R, Van Nest GA. (1999). The adjuvants MF59 and LT-K63 enhance the mucosal and systemic immunogenicity of subunit influenza vaccine administered intranasally in mice. Vaccine, 17 (7-8): 695-704.
12. Greer CE, Petracca R, Buonamassa DT, Di Tommaso A, Gervase B, Reeve RL, et al. (2001). The comparison of the effect of LTR72 and MF59 adjuvants on mouse humoral response to intranasal immunization with human papillomavirus type 6b (HPV-6b) virus-like particles. Vaccine, 19 (9-10): 1008-12.
13. de Haan A, Geerligs HJ, Huchshorn JP, van Scharrenburg G J M, Palache AM, Wilschut J. (1995). Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an coadministered liposomes. Vaccine, 13: 155-62.
14. Guy B, Pascal N, Françon A, Bonnin A, Gimenez S, Lafay-Vialon E, et al. (2001). Design, characterization and preclinical efficacy of a cationic lipid adjuvant for influenza split vaccine. Vaccine, 19: 1794-805.
15. Ray R, Glaze BJ, Moldoveanu Z, Compans RW. (1985). Intranasal immunization with envelop glycoproteins of human parainfluenza virus type 3. J Infect Dis, 157: 648-54.
16. Plante M, Jones T, Allard F, Torossian K, Gauthier J, St-Felix N, et al. (2001). Nasal immunization with subunit proteosome influenza vaccines induces serum HAI, mucosal IgA and protection against influenza challenge. Vaccine, 20 (1-2): 218-25.
17. Bacon A, Makin J, Sizer PJ, Jabbal-Gill I, Hinchcliffe M, Illum L, et al. (2000). Carbohydrate biopolymers enhance antibody response to mucosally delivered vaccine antigens. Infect Immun, 68 (10): 5764-70.
18. Nally JE, Artiushin S, Sheoran AS, Burns PJ, Simon B, Gilley RM, et al. 2000. Induction of mucosal and systemic antibody specific for SeMF3 of Streptococcus equi by intranasal vaccination using a sucrose acetate isobutyrate based delivery system. Vaccine, 19: 492-7.
19. Shahin R, Leef M, Eldridge J, Hudson M, Gilley R. (1995). Adjuvanticity and protective immunity elicited by Bordetella pertussis antigens encapsulated in poly (DL-lactide-coglycolide) microspheres. Infect Immun, 63: 1195-200.
20. Jabbal-Gill I, Lin W, Kistner O, Davis SS, Illum L. (2001). Polymeric lamellar substrate particles for intranasal vaccination. Adv Drug Deliv Rev, 51: 97-111.
21. van der Lubben IM, Kersten G, Fretz MM, Beuvery C, Verhoef JC, Junginger HE. (2003). Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine, 21 (13-14): 1400-8.
22. McInnes F, Thapa P, Stevens H, Baillie A, Watson D, Nolan A, et al. (2000). Nasal absorption of nicotine in sheep from a lyophilised insert formulation. AAP Pharm Sci 2000 AAPS Annu Meet, (Suppl 2): 2121.
23. Werner U, Damgé C, Maincent P, Bodmeier R. (2004). Properties of in situ gelling nasal insert containing estradiol/methyl β-cyclodextrin. J Drug Del Sci Tech, 14 (4), 275-84.
24. Sinyakov MS, Kharitonenkov IG, Arefev IM, Eskov AP. (1980). Influenza virus hemagglutinin: hydrodynamic properties and molecular weight. Vopr Virusol, 1: 42-5.
25. Weis W, Brown JH, Cusack S, Paulson JC, Skehel JJ, Wiley DC. (1988). Structure of the influenza virus hemagglutinin complexed with its receptor, sialic acid. Nature, 333: 426-31.
26. Fernández-Urrusuno R, Calvo P, Remuñán-López C, Vila-Jato JL, Alonso MJ. (1999). Enhancement of nasal absorption of insulin using chitosan nanoparticles. Pharm Res, 16 (10): 1576-81.
27. McNeela EA, O'Connor D, Jabbal-Gill I, Illum L, Davis SS, Pizza M, et al. (2000). A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM197) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine, 19: 1188-98.
28. Jiao Y, Ubrich N, Marchand-Arvier M, Vigneron C, Hoffman M, Lecompte T, et al. (2002). In vitro and in vivo evaluation of oral heparin-loaded polymeric nanoparticles in rabbits. Circulation, 105 (2): 230-5.
29. MacLaughlin FC, Mumper RJ, Wang J, Tagliaferri JM, Gill I, Hinchcliffe M, et al. (1998). Chitosan and depolymerized chitosan oligomers as condensing carriers for in vivo plasmid delivery. J Control Release, 56 (1-3), 259-72.
30. Bally MB, Harvie P, Wong F M P, Kong S, Wasan EK, Reimer DL. (1999). Biological barriers to cellular delivery of lipid-based DNA carriers. Adv Drug Deliv Rev, 38 (3): 291-315.
31. Davis SS. (2001). Nasal vaccines. Adv Drug Deliv Rev, 51: 21-42.
32. Nilsson S. (1995). Interactions between water-soluble cellulose derivatives and surfactants: 1. The HPMC/SDS/water system. Macromolecules, 28: 7837-44.
33. Boulmedarat L, Grossiord JL, Fattal E, Bochot A. (2003). Influence of methyl-β-cyclodextrin and liposomes on rheological properties of Carbopol 974P NF gels. Int J Pharm, 254 (1), 59-64.
34. Gutierrez de Rubalcava C, Rodriguez JL, Duro R, Alvarez-Lorenzo C, Concheiro A, Seijo B. (2000). Interactions between liposomes and hydroxypropyl methyl cellulose. Int J Pharm, 203 (1-2): 99-108.
35. Marttin E, Schipper N G M, Verhoef JC, Merkus F W H M. (1998). Nasal mucociliary clearance as a factor in nasal drug delivery. Adv Drug Deliv Rev, 29: 13-38.
36. Ishizaka S, Sugawara I, Hasuma T, Morisawa S, Möller G. (1980). Immune responses to xanthan gum I. The characteristics of lymphocyte activation by xanthan gum, Eur J Immunol, 13: 225-31.
37. Hersey SJ, Jackson RT. (1987). Effect of bile salts on nasal permeability in vitro. J Pharm Sci, 76 (12): 876-9.
38. Donovan MD, Flynn GL, Amidon GL. (1990). The molecular weight dependence of nasal absorption: The effect of absorption enhancers. Pharm Res, 7 (8): 808-15.
39. Hamman JH, Stander M, Junginger HE, Kotze AF. (2000). Enhancement of paracellular drug transport across mucosal epithelial by N-trimethylchitosan chloride. STP Pharm Sci, 10: 35-8.
40. Skehel JJ, Bayley PM, Brown EB, Martin SR, Waterfield MD, White JM, et al. (1982). Changes in the conformation of influenza virus hemagglutinin at the pH optimum of virusmediated membrane fusion. Proc Natl Acad Sci USA, 79 (4): 968-72.
41. Izumrudov VA, Zhiryakova MV. (1999). Stability of DNA-containing interpolyelectrolyte complexes in water-salt solutions. Macromol Chem Phys, 200: 2533-40.